Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40

Table 2

Summary of data from subjects who did and did not undergo additional SMDLP.

Variable	Treatment group
	No additional SMDLP	Additional SMDLP
Eyes,	21	11
Sex, (%)
Male	17 (81.0)	7 (63.6)
Female	4 (19.0)	4 (36.4)
Age, mean (SD), years	68.48 (10.63)	63.82 (7.25)
BCVA (SD), log MAR
Baseline	0.4062 (0.3071)	0.2297 (0.2108)
1 month	0.3599 (0.3262)	0.1839 (0.2255)
3 months	0.3687 (0.3101)	0.2281 (0.2308)
6 months	0.3777 (0.3788)	0.2132 (0.2255)
12 months	0.3476 (0.3535)	0.1939 (0.2390)
CMT (SD), m
Baseline	393.524 (99.622)	383.727 (89.608)
1 month	369.809 (108.959)	377.909 (97.217)
3 months	313.857 (111.305)	391.091 (84.911)
6 months	267.095 (104.461)	372.000 (80.554)
12 months	266.240 (86.214)	400.182 (79.328)
TMV (SD), mm^3
Baseline	8.1168 (0.7531)	8.2109 (1.2705)
1 month	8.0005 (0.6299)	8.2080 (1.0580)
3 months	7.8533 (0.6394)	8.322 (1.0524)
6 months	7.49 (0.3861)	7.99 (0.8307)
12 months	7.5547 (0.4610)	7.9929 (0.5118)

BCVA: best-corrected visual acuity; BRVO: branch retinal vein occlusion; SMDLP: subthreshold micropulse diode laser photocoagulation; CMT: central macular thickness; TMV: total macular volume.